Jorma J. de Ronde

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

Jorma J. de Ronde, Juliane Hannemann, Hans Halfwerk et al. · Breast Cancer Research and Treatment · 2009 · 168 citations · Full text

Surgical Oncology, Breast Oncology, Medicine +10

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue

Lorenza Mittempergher, Jorma J. de Ronde, Marja Nieuwland et al. · PLoS ONE · 2011 · 151 citations · Full text

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

Esther H. Lips, Lennart Mulder, Jorma J. de Ronde et al. · Breast Cancer Research and Treatment · 2013 · 114 citations · Full text

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

Esther H. Lips, Lennart Mulder, Jorma J. de Ronde et al. · Breast Cancer Research and Treatment · 2011 · 85 citations

Breast Oncology, Medicine, Immunology +10

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer

Jorma J. de Ronde, Esther H. Lips, Lennart Mulder et al. · Breast Cancer Research and Treatment · 2012 · 60 citations

Tumor Biology, Breast Oncology, Oncology +10